PMID- 15853209
OWN - NLM
STAT- MEDLINE
DCOM- 20050511
LR  - 20181201
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 32
IP  - 4
DP  - 2005 Apr
TI  - [Novel immunotherapeutic approach].
PG  - 453-7
AB  - Malignant astrocytoma is the most common primary brain tumor in adults. The 
      median survival time of patients with high-grade malignant astrocytoma is about 1 
      year, despite aggressive treatment with surgical resection, radiotherapy, and 
      cytotoxic chemotherapy. Novel therapeutic approaches are therefore needed to 
      prolong survival. Immunotherapy is one such novel approach that has been 
      investigated for application with different types of tumors, including brain 
      tumors. The author reviews immunotherapeutic approaches for malignant gliomas and 
      the relevance of recent clinical trials and their outcomes. A number of 
      potentially targetable antigens have been identified in gliomas. Both tenascin 
      and epidermal growth factor receptor (EGFR) have been studied extensively as 
      targets for direct immune attack via specific antibodies. As a novel target, 
      interleukin 13 receptor alpha 2-chain (IL-13 R alpha 2) has been identified. 
      IL-13 R alpha 2 is abundantly and specifically overexpressed in glioblastoma 
      multiforme, and recently a MHC class I-restricted CTL epitope has been 
      identified. Dendritic cells (DCs) are professional antigen presenting cells 
      (APCs) that have a unique potency for activating T cells. DCs have been 
      investigated in several clinical trials in patients with malignant tumors 
      including malignant gliomas. So far, seven papers concerning immunotherapy with 
      DCs against malignant gliomas have been published. These reports demonstrate that 
      immunotherapy with DCs induces immune responses and clinically antitumor effects 
      in some patients with malignant glioma. In addition, none of these studies 
      reported evidence of autoimmune neurotoxicity.
FAU - Kikuchi, Tetsuro
AU  - Kikuchi T
AD  - Dept of Oncology, Institute of DNA Medicine, The Jikei University School of 
      Medicine, Japan.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Immunotoxins)
RN  - 0 (Interleukin-13)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Astrocytoma/radiotherapy/*therapy
MH  - Brain Neoplasms/radiotherapy/*therapy
MH  - Dendritic Cells/immunology
MH  - ErbB Receptors/immunology
MH  - Glioma/radiotherapy/*therapy
MH  - Humans
MH  - *Immunotherapy
MH  - Immunotoxins/therapeutic use
MH  - Interleukin-13/immunology
MH  - Radioimmunotherapy
RF  - 23
EDAT- 2005/04/28 09:00
MHDA- 2005/05/12 09:00
CRDT- 2005/04/28 09:00
PHST- 2005/04/28 09:00 [pubmed]
PHST- 2005/05/12 09:00 [medline]
PHST- 2005/04/28 09:00 [entrez]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2005 Apr;32(4):453-7.